Uses of Bividia 100

Bividia 100 belongs to the group of Hormones, hormones, used in the treatment of type 2 diabetes. Let's learn about Betagine drug information through the article below.

Bividia 100 is an oral medication for the treatment of high blood sugar. The drug is prepared in the form of film-coated tablets, with the main ingredient being Sitagliptin (in the form of Sitagliptin phosphate monohydrate) content of 100mg and other excipients just enough for 1 tablet.
The drug works to increase insulin synthesis and release from beta cells, while decreasing Glucagon secretion from alpha cells of the pancreas. It thus helps to reduce plasma glucose concentration and inhibits hepatic glucose production. The drug is also effective in controlling blood sugar levels in patients with type 2 diabetes.

Bividia 100 is used in adults to treat type 2 diabetes, it can be used alone or in combination with other drugs to achieve treatment goals.
Monotherapy: Sitagliptin is used when patients have changed their diet, exercised but still have not controlled blood sugar levels, who have contraindications or intolerance to Metformin drug.
Combination therapy with a 2-drug regimen:
Combined with Metformin when changing diet, exercise and Metformin monotherapy fails to control blood sugar appropriately. Combined with a sulfonylurea when dietary changes, exercise, and maximum doses of sulfonylureas still fail to control blood sugar or when the patient has a contraindication or intolerance to Metformin. In combination with a PPARγ agonist (thiazolidinediones) when used as monotherapy with diet and exercise, does not provide adequate glycemic control. Combination therapy with 3-drug regimen:
Combined with Metformin and Sulfonylurea when using these two drugs with diet, exercise still does not control blood sugar appropriately. In combination with Metformin and a PPARγ agonist, when these two drugs are taken with diet and exercise, they still fail to provide adequate glycemic control. The drug can also be combined with insulin (with or without Metformin) when insulin with diet, exercise still does not control blood sugar appropriately.

The recommended dose is 100 mg/time/day, with or without food.
When Sitagliptin is used in combination with a Sulfonylurea or Insulin, a reduction in the dose of the Sulfonylurea or Insulin may be considered to reduce the risk of hypoglycaemia.
Need to adjust the dose of the drug when used in patients with impaired renal function:
Mild renal impairment (Creatinin clearance ≥ 50 mL min): no dose adjustment required. Moderate renal impairment (30 ≤ Creatinine clearance < 50mL/min): 50mg/time/day. Severe renal impairment (Creatine clearance < 30 mL/min), or end-stage renal disease requiring hemodialysis or peritoneal dialysis: 25 mg orally once a day, can be taken at any time, regardless of hemodialysis time. Because dose adjustment is based on renal function, renal function should be assessed prior to initiation of therapy and periodically thereafter.
No dose adjustment is required when used in the elderly or in patients with mild to moderate hepatic impairment. Do not use Bividia 100 for people who are hypersensitive to Sitagliptin or any of its ingredients.

When using Bividia 100, you may experience unwanted effects such as:
Hypoglycemia. Headache, dizziness. Abdominal pain, nausea, vomiting, diarrhea, constipation, acute pancreatitis Skin itching, rash, urticaria, angioedema Renal impairment, acute renal failure During the use of the drug, if any appear Any unusual symptoms that are serious should immediately call a doctor or medical staff for guidance and timely treatment.

When used concurrently Bividia may interact with the following drugs:
Sitagliptin has no significant effect on the pharmacokinetics of the following drugs: Metformin, Rosiglitazone, Glyburide, Simvastatin, Warfarin and oral contraceptives . The drug has little effect on the plasma concentration of Digoxin when used in combination.

When using Bividia 100, caution should be exercised in the following cases:
The drug should not be used in patients with type 1 diabetes or diabetic ketoacidosis. Combination therapy with a sulfonylurea or insulin may increase the risk of hypoglycaemia, so a dose reduction of these two agents should be considered. Hypersensitivity reactions such as anaphylaxis, angioedema, and exfoliative skin diseases (Stevens-Johnson syndrome) may occur after administration of the drug, in which case the drug should be discontinued immediately and other potential causes investigated. and at the same time replace with other therapies to treat the disease. The safety and effectiveness of Sitagliptin when used in children under 18 years of age have not been established, so it should not be used in this population. There are not enough research data on the use of the drug in pregnant and lactating women, so its use in these subjects is not recommended. The drug can cause dizziness, so caution should be exercised in people who must drive or operate machinery. Above is some information about the use of Bividia 100, if you need advice or have any questions, please consult a qualified doctor / pharmacist for advice.